Northland Securities reissued their buy rating on shares of Apollo Endosurgery, Inc. (NASDAQ:APEN) in a report issued on Friday morning.
“We maintain our constructive stance on the name, however are tweaking our FY18 #’s down to reflect any Orbera impacts.”,” Northland Securities’ analyst commented.
A number of other research firms have also recently weighed in on APEN. ValuEngine cut Apollo Endosurgery from a sell rating to a strong sell rating in a research report on Thursday, August 3rd. Craig Hallum started coverage on Apollo Endosurgery in a research report on Monday, July 24th. They issued a buy rating and a $11.00 price objective for the company. Finally, Roth Capital started coverage on Apollo Endosurgery in a research report on Wednesday, August 2nd. They issued a buy rating and a $10.00 price objective for the company.
Shares of Apollo Endosurgery (NASDAQ APEN) traded down 3.47% on Friday, hitting $4.13. The stock had a trading volume of 82,365 shares. The company’s market cap is $71.25 million. Apollo Endosurgery has a 12 month low of $2.00 and a 12 month high of $21.88. The company’s 50 day moving average price is $4.69 and its 200-day moving average price is $6.19.
Apollo Endosurgery (NASDAQ:APEN) last posted its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.40). The business had revenue of $17.14 million during the quarter. Apollo Endosurgery had a negative return on equity of 113.42% and a negative net margin of 62.31%. On average, analysts expect that Apollo Endosurgery will post ($2.07) earnings per share for the current year.
WARNING: “Apollo Endosurgery, Inc. (APEN) Receives “Buy” Rating from Northland Securities” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/28/apollo-endosurgery-inc-apen-receives-buy-rating-from-northland-securities.html.
About Apollo Endosurgery
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc. and related companies with MarketBeat.com's FREE daily email newsletter.